Skip to main content
Premium Trial:

Request an Annual Quote

IntegenX Acquires DNA Consumables Portfolio from GE Healthcare

NEW YORK (GenomeWeb News) – IntegenX today said that it has acquired a portfolio of DNA consumables products from GE Healthcare Bio-Sciences' subsidiary SV Corp.

The acquisition provides Pleasanton, Calif.-based IntegenX with an IP estate covering capillary electrophoresis, separation, sample preparation, and separation matrix technologies, according to IntegenX CEO Stevan Jovanovich.

IntegenX will take over supplying capillaries and matrix to "the more than 100 existing users of GE's MegaBace sequencers," the firm said. Financial and other terms of the deal were not disclosed.

IntegenX intends to integrate the acquired products into its RapidHit 200 Human DNA Identification System, which is scheduled for launch later this year.

The RapidHIT 200 is a sample-to-profile biometric system for real-time human DNA analysis, and according to IntegenX is the first fully automated DNA identification technology that can produce DNA profiles from buccal swabs or other human samples in less than 90 minutes.

Late last year, IntegenX raised $40 million in a Series C round to support further development and commercialization of the system.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.